Agios Pharmaceuticals
AGIO
206 hedge funds and large institutions have $2.51B invested in Agios Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 51 increasing their positions, 82 reducing their positions, and 27 closing their positions.
78% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 27
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38% more capital invested
Capital invested by funds: $1.81B → $2.51B (+$695M)
10% more funds holding
Funds holding: 187 → 206 (+19)
6% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $11.8M
7.91% less ownership
Funds ownership: 110.34% → 102.43% (-7.9%)
38% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 82
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$43M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$30.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.6M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$16.8M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$36.9M |
| 2 |
AC
Armistice Capital
New York
|
-$31.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$31.7M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$27.2M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$26M |
AGIO Hedge Fund Activity: Q2 2024 in Review
206 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2024, worth a combined $2.51B — up 38% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new AGIO positions and 27 closed out — a net gain of 21 holders — while 51 added to existing stakes and 82 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $43M. The largest seller was State Street, cutting an estimated $36.9M.
- 206 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2024, up from 187 in Q1 2024.
- Funds reported $2.51B of Agios Pharmaceuticals stock for Q2 2024, up 38% quarter-over-quarter.
- 48 funds opened new Agios Pharmaceuticals positions in Q2 2024 and 27 closed out, a net change of +21 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2024 was BVF Inc, an estimated $43M added.
- The largest Agios Pharmaceuticals seller in Q2 2024 was State Street, an estimated $36.9M sold.
Based on aggregated 13F filings for Q2 2024.